Timothy C. Thompson
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (17)
Supplementary Table S13. Quantification of each protein-specific band normalized to vinculin (macrophage cells (RAW264.7) mono- or cocultured with RM-1-BM EV or SPOPmut models under treatment with OLA, Fig. 5E).
Year:
2025
Supplementary Fig. S19. Heatmaps of common differentially expressed genes in co-cultured and mono-cultured prostate cancer model tumor cells demonstrating significant (FDR
Year:
2025
Supplementary Fig. S21. Double immunofluorescence staining analysis of cleaved caspase 3 and PARP1 in C4-2b-empty vector and C4-2b-SPOPF133V xenograft tumors treated with talazoparib (TALA) or control vehicle
Year:
2025
Supplementary Table S3. Complete listing of antibodies used for immunoblotting (IB) and immunostaining analysis (Fig. 6C, 6D and Extended Data Fig. 5, 6). Vendor and catalog numbers are included in the list.
Year:
2025
Supplementary Table S2. Listing of protein features differentially expressed in Dox-inducible SPOPmut (F102C and F133V) C4-2b prostate cancer cells compared to C4-2b vector control shown in Fig. 2A upper panel
Year:
2025
Supplementary Fig. S21. Double immunofluorescence staining analysis of cleaved caspase 3 and PARP1 in C4-2b-empty vector and C4-2b-SPOPF133V xenograft tumors treated with talazoparib (TALA) or control vehicle
Year:
2024
Supplementary Fig. S19. Heatmaps of common differentially expressed genes in co-cultured and mono-cultured prostate cancer model tumor cells demonstrating significant (FDR
Year:
2024
Supplementary Fig. S19. Heatmaps of common differentially expressed genes in co-cultured and mono-cultured prostate cancer model tumor cells demonstrating significant (FDR
Year:
2024
Purpose: Speckle-type POZ protein (SPOP) is important in DNA damage response (DDR) and maintenance of genomic stability. Somatic heterozygous missense mutations in the SPOP1 substrate-binding cleft are found in up to 15% of prostate cancers. While mutations in SPOP predict for benefit from androgen receptor signaling inhibition (ARSi) therapy, outcomes for patients with SPOP-mutant (SPOPmut) prostate cancer are heterogeneous and targeted treatments for SPOPmut castrate-resistant prostate cancer (CRPC) are lacking. Experimental Design: Using in silico genomic and transcriptomic tumor data, proteomics analysis and genetically modified cell line models we demonstrate mechanistic links between SPOP mutations, STING signaling alterations and PARP inhibitor vulnerabilities. Results: We demonstrate that SPOP mutations are associated with upregulation of a 29-gene non-canonical (NC) STING1 (NC-STING) signature in a subset of SPOPmut, treatment-refractory CRPC patients. We show in preclinical CRPC models that SPOP targets and destabilizes STING protein, and prostate cancer ̶ associated SPOP mutations result in upregulated NC-STING-NF-κB signaling and macrophage- and tumor microenvironment (TME)-facilitated reprogramming, leading to tumor cell growth. Importantly, we provide in vitro and in vivo mechanism-based evidence that PARP inhibitor (PARPi) treatment results in a shift from immunosuppressive NC-STING-NF-κB signaling to anti-tumor, canonical cGAS-STING-IFN-β signaling in SPOPmut CRPC and results in enhanced tumor growth inhibition. Conclusions: We provide evidence that SPOP is critical in regulating immunosuppressive versus anti-tumor activity downstream of DNA damage-induced STING activation in prostate cancer. PARPi treatment of SPOPmut CRPC alters this NC-STING signaling toward canonical, anti-tumor cGAS-STING-IFN-β signaling, highlighting a novel biomarker-informed treatment strategy for prostate cancer.
Year:
2024
Supplementary Table S3. Complete listing of antibodies used for immunoblotting (IB) and immunostaining analysis (Fig. 6C, 6D and Extended Data Fig. 5, 6). Vendor and catalog numbers are included in the list.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (6)
Johannes Fahrmann
Assistant Professor
The University of Texas MD Anderson Cancer Center
Massimo Loda
Chair
Weill Cornell Medical College
Jody Vykoukal
Group Leader
The University of Texas MD Anderson Cancer Center
Samir M. Hanash
The University of Texas MD Anderson Cancer Center
Paul Corn
Chair
The University of Texas MD Anderson Cancer Center
Timothy Yap
The University of Texas MD Anderson Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.